Zynerba Pharmaceuticals (ZYNE)

[Fress]

Our Time is coming.

Those with a decent position and a little bit of patience are going to make a lot of money here.

Load more at these prices.


And then lock up your shares ASAP.


I am expecting a big jump to close out Q2 End of May 2 weeks.


Perhaps 30 percent to 40 percent gains is possible just in the next two weeks.


Stock is very significantly undervalued.


$40.00-$50.00 end of 2019.
-------------------------------------------------------------------------------------------------------
https://www.medicalbag.com/home/medicine/cbd-gel-gets-fast-tracked-for-behavioral-symptoms-associated-with-fragile-x-syndrome/

May 9, 2019
CBD Gel Gets Fast Tracked for Behavioral Symptoms Associated With Fragile X Syndrome
Steve Duffy

Zygel is a clear gel formulation of CBD designed for transdermal administration.
The Food and Drug Administration (FDA) has granted Fast Track designation to Zygel (ZYN002; Zynerba), a cannabidiol gel for the treatment of behavioral symptoms associated with Fragile X syndrome (FXS).

Fragile X is a rare inherited syndrome of intellectual disability and autism. Mutations occur in the FMR1 gene which can block expression of the Fragile X Mental Retardation Protein (FMRP), an important protein in GABA synthesis.

The safety and efficacy of the transdermal gel will be evaluated in a placebo-controlled study involving 204 patients with FXS. The primary outcome measure of the study will be the change from baseline to end of treatment (Week 14) in the Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) pre-specified subscale; the ABC-C is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials.


Practice Restrictions for Buprenorphine Prescribing Among Nurse Practitioners, Physician Assistants
More Than Half of US Adults Have Medical Financial Hardship
Implementing Surgical Safety Checklist Reduces Mortality
“The FDA’s decision to grant Fast Track Designation for Zygel underscores the significance and severity of the unmet medical need that exists for patients living with Fragile X Syndrome and their caregivers,” said Armando Anido, Chairman and Chief Executive Officer of Zynerba. “We believe that Zygel has the potential to be the first treatment indicated to directly address the core behavioral symptoms of this syndrome.”


Zygel is also being assessed in 2 separate phase 2 studies, one in children with developmental and epileptic encephalopathy and another in patients with autism spectrum disorder.
-------------------------------------------------------------------------------------------------------
Why ZYNE going way higher. FRAGILE X CBD GEL Phase 2 showed 55% improvement by week-12, improved by 75%
12months.Fragile FX no FDA drug +Autism & epilepsy n PH3.


800 Million Revenue Potential from Fragile X NO FDA Approved Drugs.

Company has team in place that has taken drugs from pre clinical to FDA Approval. CEO last 2 Biotech companies where bought out. 800 Million revenue in Fragile X makes ZYNE a multi billion dollar company.

ZYNE market cap today 280 Million Market Cap. Only 18 Million shares This could surge soon to new all time highs. 3.0 Version of GWPH

The all-time high Zynerba Pharmaceuticals stock price is 36.49, which is 200% above the current share price.





FDA fast tracking gets approval 80% of the time in the last 2 years. No approved drug for Fragile X





$ZYNE